Cargando…

Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor

BACKGROUND: Imatinib mesylate is an effective treatment for metastatic gastrointestinal stromal tumor (GIST). However, most patients eventually develop resistance and there are few other treatment options. Immunotherapy using genetically modified or designer T cells (dTc) has gained increased attent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katz, Steven C, Burga, Rachel A, Naheed, Seema, Licata, Lauren A, Thorn, Mitchell, Osgood, Doreen, Nguyen, Cang T, Espat, N Joseph, Fletcher, Jonathan A, Junghans, Richard P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599052/ https://www.ncbi.nlm.nih.gov/pubmed/23433424 http://dx.doi.org/10.1186/1479-5876-11-46

Ejemplares similares

Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor modified T cell infusions for liver metastases
por: Saied, Abdul, et al.
Publicado: (2014)

Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
por: Katz, Steven, et al.
Publicado: (2016)

Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours
por: Huang, Mengyuan, et al.
Publicado: (2019)

Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2019)

Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal Tumor
por: Mühlenberg, Thomas, et al.
Publicado: (2015)

Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors
por: Obata, Y, et al.
Publicado: (2017)

Frequent KIT Mutations in Human Gastrointestinal Stromal Tumors
por: Xu, Zhi, et al.
Publicado: (2014)

C-Kit-Negative Gastrointestinal Stromal Tumor in the Stomach
por: Seo, Ho Seok, et al.
Publicado: (2015)

Gastrointestinal stromal tumor with KIT mutation in neurofibromatosis type 1
por: Namgung, Hwan
Publicado: (2011)

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors
por: Caenepeel, Sean, et al.
Publicado: (2010)

Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis
por: Ke, Hengning, et al.
Publicado: (2016)

KCTD12 is negatively regulated by Kit in gastrointestinal stromal tumors
por: Suehara, Yoshiyuki, et al.
Publicado: (2018)

Morphological Correlates of KIT and PDGFRA Genotypes in Gastrointestinal Stromal Tumour
por: Priya, Valli, et al.
Publicado: (2020)

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors
por: Gao, Jing, et al.
Publicado: (2016)

Gastrointestinal Stromal Tumours treated before and after the advent of c-kit immunostaining
por: Sorelli, Paolo G, et al.
Publicado: (2011)

Spectrum of the KIT Gene Mutations in Gastrointestinal Stromal Tumors in Arab Patients
por: Faiyaz-Ul-Haque, Muhammad, et al.
Publicado: (2018)

KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors
por: Palomba, Grazia, et al.
Publicado: (2020)

Discovery of novel potential KIT inhibitors for the treatment of gastrointestinal stromal tumor
por: Jiang, Lili, et al.
Publicado: (2021)

Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)
por: Heinrich, Michael C., et al.
Publicado: (2019)

The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting
por: Maleddu, Alessandra, et al.
Publicado: (2011)

The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

Gastrointestinal Stromal Tumors with KIT Mutation Coexisting with Wild-type Gastrointestinal Stromal Tumors in a Patient with Neurofibromatosis Type 1
por: Li, Yang, et al.
Publicado: (2018)

Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors
por: Pantaleo, Maria A, et al.
Publicado: (2014)

A Case of KIT-Negative Extra-Gastrointestinal Stromal Tumor of the Lesser Omentum
por: Ogawa, Hisataka, et al.
Publicado: (2012)

Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor
por: Zhang, Dengyang, et al.
Publicado: (2022)

Mutational Analysis of c-KIT and PDGFRA in Canine Gastrointestinal Stromal Tumors (GISTs)
por: Morini, Maria, et al.
Publicado: (2022)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Erratum to: The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism
por: Théou-Anton, N, et al.
Publicado: (2006)

Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors
por: Merkelbach-Bruse, Sabine, et al.
Publicado: (2010)

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis
por: Zong, Liang, et al.
Publicado: (2014)

ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours
por: Gromova, Petra, et al.
Publicado: (2012)

Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors
por: Rossi, Sabrina, et al.
Publicado: (2016)

C‐kit Gene Abnormalities in Gastrointestinal Stromal Tumors (Tumors of Interstitial Cells of Cajal)
por: Sakurai, Shinji, et al.
Publicado: (1999)

A meta-analysis of prognostic value of KIT mutation status in gastrointestinal stromal tumors
por: Jiang, Zhiqiang, et al.
Publicado: (2016)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

KIT Mutation in Gastric Gastrointestinal Stromal Tumor in a Patient With Familial Paraganglioma Syndrome Type 4
por: Houlden, Robyn L., et al.
Publicado: (2021)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Gastrointestinal Stromal Tumours: An Update
por: Somerhausen, Nicolas De Saint Aubain, et al.
Publicado: (1998)

Overcoming heterogenity in imatinib-resistant gastrointestinal stromal tumor
por: Serrano, César, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q2hgijhifnkkqdr3vc94nnok97